新股消息 | 贝达药业递表港交所 已成功转型为一家“平台型制药企业”

Core Viewpoint - Beida Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, marking its third attempt to go public in Hong Kong after two unsuccessful attempts in 2021 [1][4]. Group 1: Company Overview - Beida Pharmaceutical is a pioneer in China's innovative drug research and development industry, successfully transforming from a biotech company focused on innovative drug discovery to a leading and profitable biopharmaceutical company [4]. - The company has established an integrated platform driven by four core pillars: mature commercialization capabilities, comprehensive drug discovery and development capabilities, forward-looking business development layout, and a competitive innovation ecosystem [4]. Group 2: Product Pipeline and Market Position - Beida Pharmaceutical has launched eight commercialized products, including five innovative drugs and one biosimilar, achieving several "firsts" in China [5]. - The company has built a comprehensive drug pipeline targeting key lung cancer pathways, including EGFR and ALK, and is expanding into high-potential treatment areas such as breast cancer, kidney cancer, hematology, and ophthalmology [4][5]. Group 3: Financial Performance - For the fiscal years ending December 31, 2022, 2023, 2024, and the six months ending June 30, 2025, Beida Pharmaceutical reported revenues of approximately RMB 2.377 billion, RMB 2.456 billion, RMB 2.892 billion, and RMB 1.731 billion respectively [5][7]. - The annual profits for the same periods were approximately RMB 125 million, RMB 334 million, RMB 387 million, and RMB 131 million respectively [5][7].